GT Biopharma
GTBP
42 hedge funds and large institutions have $657K invested in GT Biopharma in 2026 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 10 closing their positions.
76% more capital invested
Capital invested by funds: $374K → $657K (+$283K)
50% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 10
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
11% more funds holding
Funds holding: 38 → 42 (+4)
0.57% more ownership
Funds ownership: 4.54% → 5.11% (+0.57%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$150K |
| 2 |
AAP
Arax Advisory Partners
Denver,
Colorado
|
+$51.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$25.1K |
| 4 |
I
INVST
Indianapolis,
Indiana
|
+$12.8K |
| 5 |
KP
Keel Point
Huntsville,
Alabama
|
+$11.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SRL
Scientech Research LLC
Jersey City,
New Jersey
|
-$43K |
| 2 |
Jane Street
New York
|
-$20.4K |
| 3 |
HF
HRT Financial
New York
|
-$9K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$8.51K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$7.96K |
GTBP Hedge Fund Activity: Q1 2026 in Review
42 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q1 2026, worth a combined $657K — up 76% from $374K a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new GTBP positions and 10 closed out — a net gain of 5 holders — while 7 added to existing stakes and 5 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $150K. The largest seller was Scientech Research LLC, exiting entirely with an estimated $43K sold.
- 42 institutional investors held GT Biopharma (GTBP) as of Q1 2026, up from 38 in Q4 2025.
- Funds reported $657K of GT Biopharma stock for Q1 2026, up 76% quarter-over-quarter.
- 15 funds opened new GT Biopharma positions in Q1 2026 and 10 closed out, a net change of +5 holders.
- The largest GT Biopharma buyer in Q1 2026 was Geode Capital Management, an estimated $150K added.
- The largest GT Biopharma seller in Q1 2026 was Scientech Research LLC, an estimated $43K sold.
Based on aggregated 13F filings for Q1 2026.